Structure Therapeutics Inc.
- GPCR
- NASDAQ
- Biotechnology
- Oral Peptide Therapeutics
- Chronic Disease Drug Development
- GPCR-Targeted Therapies
$21.75
Today +3.18%Quote Oct 19, 2026, 04:59 PM UTC
−39.94%over the last month
Max drawdown −42.9%From 1-month high −42.9%3 months −55.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Structure Therapeutics
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
281
Market value
$4.65B
Quote Oct 19
Floor
$21.23
2.4% below price
Resistance
$23.16
6.5% above price
Price vs analyst targets
14 analysts
Lowest target
$70.00Highest target
$111.00
$70.00Highest target
$111.00
- Price $21.75
- Average target $90.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 316% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GPCRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free